Insider Selling: Phreesia (NYSE:PHR) General Counsel Sells $73,926.72 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison Hoffman sold 6,176 shares of Phreesia stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $11.97, for a total value of $73,926.72. Following the completion of the transaction, the general counsel owned 163,485 shares in the company, valued at $1,956,915.45. This represents a 3.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Phreesia Stock Performance

PHR stock opened at $10.96 on Friday. Phreesia, Inc. has a one year low of $10.75 and a one year high of $32.76. The firm has a market cap of $660.54 million, a price-to-earnings ratio of -109.55 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The firm has a 50-day simple moving average of $12.61 and a two-hundred day simple moving average of $17.89.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PHR. Canaccord Genuity Group reduced their price target on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, December 9th. Mizuho dropped their target price on Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday. Barclays reduced their target price on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 16th. Wall Street Zen cut Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, Citigroup dropped their target price on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, January 9th. Seventeen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Phreesia has a consensus rating of “Moderate Buy” and an average target price of $28.65.

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Phreesia by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock valued at $97,194,000 after acquiring an additional 39,540 shares during the period. Greenhouse Funds LLLP increased its stake in shares of Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after acquiring an additional 557,265 shares during the period. Granahan Investment Management LLC raised its holdings in shares of Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after purchasing an additional 1,018,987 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Phreesia by 28.8% during the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock worth $33,841,000 after purchasing an additional 446,890 shares during the last quarter. Finally, Nuveen LLC lifted its holdings in shares of Phreesia by 12.7% in the 4th quarter. Nuveen LLC now owns 1,875,725 shares of the company’s stock valued at $31,737,000 after buying an additional 211,262 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.